Trial 9L-14-7


A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To Or Relapsed after First-Line Treatment with or without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

Type: Treatment
Phase: Phase III
Status: Not Open (Closed)
Treatments: Chemotherapy: Systemic
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Kevin Kelly, M.D.
Other Trial Staff:  Simbiso Peresuh, Coordinator, Suraj Chandwani, D.M., Ashot Minasyan, D.M., Madelyn Lefler, Coordinator, Anastasia Philabaum, Coordinator, Christine Duran, Coordinator, Donna Fernando, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.